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Atopic eczema (AE) is one of the most common skin diseases that patients frequently present 
with to dermatological practices in South Africa (SA). It has shown to impact negatively on the 
quality of life of many patients suffering from it. Epidemiological studies have shown high rates 
of AE prevalence, ranging from 2-7% in adults and 7-20% in children. Over the last decade, the 
lifetime prevalence of physician-diagnosed AE has almost doubled in SA. This rise continues 
despite accessible effective treatments. Due to AE’s chronic and relapsing nature and the 
unattainability of complete clinical cure, patients are progressively exploring complementary and 
alternative medicines (CAM) in search of a solution. Although the global popularity of CAM for 
AE is on the rise, a review of the literature demonstrated contradictory evidence with regards to 
their efficacy with shortcomings in many of the published data thus making it difficult for 
clinicians to assess their role, if any, in the management of AE.  
 
Objective One 
To objectively evaluate the information on the efficacy and safety of CAM in light of the most 
recent findings, the study entitled “Complementary Therapy in Atopic Eczema: The Latest 
Systematic Reviews” in Chapter Two of this thesis collectively evaluated all published systematic 
reviews (SRs) to date on the most popular CAM modalities for AE. These SRs included those of 
Chinese herbal medicines (CHM), homeopathy, oral herbal remedies (including evening primrose 
oil and borage oil), probiotics and certain dietary supplements. The study concluded that none of 
the alternative therapies evaluated demonstrated obvious and indisputable evidence of efficacy 
due to many limitations in study design, poor methodologies, patient numbers etc. Further studies 
may be warranted with some therapies (CHM, different probiotic strains and fish oil), whereas 
homoeopathy failed to show any treatment effect and further studies with evening primrose oil 
and borage oil may be difficult to justify. This overview was able to provide objective information 
to enable dermatologists and general practitioners to advise and manage their patients holistically 
in the light of the most recent findings.  
 
Objective Two 
Topical corticosteroids remain the mainstay of treatment for AE. However, many patients are 
concerned about their long-term safety and thus seek evidence-based safer alternatives. Many 
published papers have made reference to the wide use of topical herbal creams for AE and many 
of these been tested, but few in controlled clinical trials. No SRs of these trials could be found, 
xx 
 
although SRs of topical herbal extracts have been published for other chronic skin conditions. 
The study entitled “Topical Herbal Medicines for Atopic Eczema: A Systematic Review of 
Randomised Controlled Trials” in Chapter Three of this thesis was the first SR to be conducted 
for topical herbal preparations for AE. Using Cochrane SR methodology, numerous databases 
were searched from inception until June 2014. All controlled clinical trials of topical herbal 
medicines for AE in humans of any age and published in English were included regardless of the 
control intervention or randomisation. Of eight studies that met the inclusion criteria, seven 
investigated extracts of single plants and one an extract from multiple plants. The study concluded 
that there is currently insufficient evidence of efficacy for any topical herbal extract in AE with 
many studies having methodological flaws. Even studies that did show efficacy over placebo were 
single trials with small patient cohorts. Together with providing clarity to both prescribers and 
patients, the study was able to identify opportunities for future research in better designed trials 
with topical extracts that showed a promising effect and had a low risk of bias across all domains. 
These were randomised controlled trials (RCTs) of licorice gel and Hypericum perforatum. 
  
Objective Three 
The literature has thus far reported on numerous international studies on the widespread use of 
CAM for AE. These studies not only investigated the prevalence of CAM use but also the 
modalities used, motivations for use and demographic variables that influence their use. All these 
factors potentially impact on the treatment of AE. No such studies conducted anywhere in Africa 
could be found. Given the lack of literature in SA, the study entitled “Complementary and 
Alternative Medicine Use amongst patients with Atopic Eczema - a South African Perspective” 
in Chapter Four of this thesis was a cross-sectional study that was conducted amongst AE patients 
in Durban, KwaZulu-Natal to bridge this gap in knowledge. This study found a 66% current or 
previous CAM use, which was moderately higher than those reported in other countries. 
Frequently used CAM were vitamins, aromatherapy oils, herbal creams, traditional African 
medicines and homeopathy. Non-disclosure to the dermatologist was high and almost half of the 
patients interviewed said they were not questioned about CAM use. More Indian patients used 
CAM and Muslims were the most frequent CAM users. Duration of AE was also a predictor of 
use. Although not statistically significant, the more educated and higher income bracket used 
CAM more. The study was able to provide detailed trends of CAM use by South Africans for AE 
which is an important addition to the literature. This information is able to highlight to 
dermatologists and healthcare professionals treating AE patients, the need to be more conversant 





Although evident from the literature that patients have embraced CAM, it is uncertain whether 
mainstream healthcare professionals are as embracing. Their attitude and knowledge of CAM will 
influence their pro-activeness in enquiring about CAM and confidently discussing 
proven/unproven remedies with their patients, thereby influencing an overall positive clinical 
experience and disease course. Several international studies have explored the knowledge, 
attitudes and practices amongst general practitioners (GPs), physicians, pharmacists, 
paediatricians, academic doctors and other healthcare workers towards CAM, but none within the 
context of a specific disease. No published studies conducted in SA or elsewhere investigating 
HCPs’ knowledge, attitudes and norms of practice with regards to CAM for AE could be found. 
As a result, and given the extensive use among SA patients with AE as per the study’s previous 
findings, a cross-sectional study entitled “Knowledge, Attitude and Practices of South African 
Healthcare Professionals towards Complementary and Alternative Medicine Use for Atopic 
Eczema - A Descriptive Survey” was conducted. Results amongst GPs, dermatologists, 
paediatricians and pharmacists are reported in Chapter Five of this thesis. GPs and pharmacists 
were significantly more embracing of CAM compared to dermatologists and paediatricians. The 
study revealed poor CAM knowledge and communication between HCPs and patients, however 
there was a strong interest to learn more. It was also found that there is an urgent need for 
continuing education programmes on CAM and inclusion into undergraduate curriculums as most 
HCPs were interested in learning more about CAM.  
 
Conclusion 
Overall, this thesis was able to fill a gap in the knowledge of CAM use for AE both globally and 
within the context of SA. The study provided clarity and objective conclusions from the many 
SRs previously published for popular oral CAM therapies. Furthermore, the study conducted and 
published the first SR on topical herbal therapies for AE. This SR identified therapies that have 
demonstrated positive results for AE with low risk of bias and is thus able to provide direction for 
future research in this regard. Within the SA context, the study described the perspectives and 
practices of both patients and mainstream healthcare professionals on CAM use for AE, which 
was lacking in Africa. With this information we were able to ascertain the popular CAM that SA 
patients are using, the extent of their use as well as establish CAM education needs for local 
healthcare professionals. 
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This chapter consists of the background of the study, the primary and secondary aim/objectives, 
the problem statement, significance of the study, as well as the structure of the entire dissertation. 
 
1.1.1.1. Atopic Eczema - Its global prevalence and impact on quality of life 
 
Atopic eczema, a chronically relapsing disease, is the commonest inflammatory skin condition; 
more common in infants and children than in adults. The exact cause of the disease is unknown, 
but familial/genetic factors are considered to play an important role in the development of the 
disease and frequency is seen in patients who have a family history of atopy or atopic diseases 
like asthma, allergic rhinitis and atopic eczema.1 Symptoms of itch and eczema which appears in 
episodic exacerbations and remissions are characteristic of the disease. 
 
Recent epidemiological studies have shown high rates of atopic eczema prevalence, ranging from 
2-7% in adults and 7-20% in children.2 The worldwide incidence in children five years and under, 
is estimated at 3-5%. Literature has revealed that approximately 49% to 75% of children with 
eczema, develop the disease by 6 months of age and, by the age of 5 years, the percentage 
increases to 80%-90%.1 The prevalence of atopic eczema seems to vary across the world in both 
adults and children. In a systematic review of epidemiological studies investigating the prevalence 
of atopic eczema between 1990-2010, data from studies done in Africa (Kenya, Morocco and 
South Africa) showed that the prevalence was increasing. The data was attained mostly from 
children 13-14 years of age where an approximate doubling of the lifetime prevalence of atopic 
eczema symptoms was found for South Africa [e.g. flexural rash from 10.2% in 1995 to 16.5% 
in 2002]. The lifetime prevalence of physician-diagnosed atopic eczema in these children also 
showed an approximate doubling in South Africa and Kenya.3 
 
Skin diseases have been shown to impact negatively on the quality of life of patients affecting 
physical, social and psychological well-being. This is true for both adults and children. In a 
questionnaire based study by Finlay, assessing the impact of severe eczema on the quality of life 
in adults, a number of patients with severe eczema consider that having diabetes or hypertension 
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would be better than having eczema. The study demonstrated that over the long term, atopic 
eczema affects family life in 80% of patients and sexual relationships in 57%. Loss of income and 
days lost at work due to their eczema were also reported in many patients. These findings affirm 
that severe eczema has a major impact on the quality of life of adults.4  
 
Studies using a dermatology-specific quality-of-life instrument have shown that atopic eczema 
adversely affects a child’s quality of life significantly more than many other skin conditions 
including moles, warts, psoriasis, and alopecia.5 Furthermore, it has also been shown to affect 
quality of life more than other common childhood diseases such as asthma and diabetes.6 This 
emphasizes the significance of eczema as a major chronic childhood disease.  
 
The symptoms of atopic eczema also have a profound effect on the overall quality of life of 
parents or primary care-givers who struggle daily, coping with the child’s skin disease especially 
due to its chronic nature with unpredictable flares-ups, itching, lack of sleep and the 
inconvenience and cost of treatments.1 Apart from the physical symptoms, there are also 
psychological and psycho-social factors involved in managing this chronic condition. The 
physical symptoms of itching and soreness often give rise to sleep deprivation. This has been 
noted in over 60% of patients, frequently leading to tiredness, mood changes and impaired 
psychosocial functioning of the child as well as care-givers and family members at school and 
work. Children often face untoward comments and embarrassment due to teasing and bullying. 
Factors such as type of clothing, vacations, sleep-overs, swimming and other sporting activities 
may be limited and thus affect the child’s and their family’s lifestyle. These may further lead to 
insecurities, depression and social withdrawal.6 
 
Lewis-Jones further reports that other factors that impact on normal family life are adherence to 
complex, rigid and often unpleasant treatment regimens, increased work in caring for a child with 
eczema, feelings of hopelessness, exhaustion and guilt when treatments do not work. The hidden 
costs involved in eczema management may significantly impact on lower income families.6  
 
1.1.1.2. Atopic Eczema - Searching for a solution (CAM) 
 
The prevalence of atopic eczema continues to rise despite the increasing number of effective 
treatments available to dermatologists. Owing to the chronic nature of the disease, finding a cost-
effective regimen that will control the disease is imperative.7 Due to the chronic, persistent and 
unrelenting nature of the disease, patients are continually exploring complementary and 
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alternative therapies in search of a cure.8 Complete clinical cure still remains unattainable and the 
increased frequency of use of complementary and alternative medicines (CAM) in the 
management of the disease has been recognised.9  
 
A review of the literature has shown that many CAM therapies may impact positively on the relief 
of symptoms like itching,8 patient and physician-assessed disease severity10 and overall health-
related quality of life in patients with atopic eczema.11-13 Other studies have demonstrated less 
convincing results from specific CAM therapies.14, 15 Regardless, the awareness and use of CAM 
is globally prominent. The widespread use of CAM for atopic eczema has made its treatment a 
matter of extreme controversy between those who favour their use and those who favour the use 
of rational, conventional medicines with proven efficacy more than any other skin disease. This 
may result in long term suffering and may be harmful as their use leads to the withholding or 
delay of effective treatment modalities.16 Considering the conflicting and inconsistent evidence 
of efficacy of commonly used alternative therapies in the literature and the shortcomings in 
available published data, it is difficult for clinicians to assess their role, if any, in management. 
The potentially serious adverse effects of some alternative therapies as well as drug-herb 
interactions are also of great concern.8, 17  
 
One of the reasons for the persisting nature of atopic eczema is the patients’ inability to comply 
effectively with medical advice. Most studies have reported a non-compliance rate of 30-60% 
with any given regimen.18 Non-compliance impacts on the overall cost of treatment, the patient’s 
confidence towards their prescribed medication thus making it more difficult for the practitioner 
to evaluate their effectiveness and prolonging the illness. Fischer explains that of the reasons cited 
for non-compliance of treatment for atopic eczema, a significant apprehension about the use of 
steroids and their potential for danger was noted (40%) together with concern about present and 
long term side effects of the prescribed medication. More than half of the patients (57%) 
expressed a preference for natural therapy as a reason for not adhering to the prescribed 
treatment.18 The search for more ‘natural therapies’ presents a problem for practitioners for many 
reasons which include the unproven effectiveness of many alternative medicines as well as the 
detraction from funds the patient has to invest in medication with proven reliability and 
perpetuation of the belief by ‘natural’ therapists that steroids are dangerous. All of this 






1.1.1.3. CAM and the Patient  
 
Numerous international studies conducted in countries e.g. Ireland8, United Kingdom9, Korea, 19 
United States 20 and Norway21 have reported on the widespread use of CAM for AE. These studies 
have qualified and quantified CAM use in atopic eczema. They not only investigated the 
prevalence of CAM use but also the modalities used, motivations for use and demographic 
variables that influence their use; all which potentially impact on the treatment of AE. A few 
South African studies have also realised the popularity of CAM 22-24, however, these studies were 
on general CAM use and its use in Human Immunodeficiency Virus (HIV). In Africa, no such 
studies have been conducted in atopic eczema.  
 
The literature has also demonstrated that patients often do not inform their conventional doctor 
about their use of CAM and the dermatologists’ ability to predict CAM use in their patients has 
been found to be poor.25 The doctors’ knowledge about a patient’s use of CAM may lead to a 
better understanding of the patient’s attitude to the disease and subsequently help to achieve better 
patient compliance.17  
 
1.1.1.4. CAM and the Healthcare Professional 
 
While it is evident in the literature that patients have embraced CAM, the healthcare providers’ 
perspective on CAM and whether they encourage or advocate alternative treatment measures and 
understand completely their potential benefits or risks, is questionable. Several international 
studies have explored the knowledge, attitude, practice and factors affecting their 
recommendation amongst general practitioners, physicians, pharmacists and other health workers 
towards complementary therapies.26-33 Given the emphasis necessitating more scientific based 
evidence in current discussions surrounding CAM, the views and rationales amongst academic 
doctors with a research orientation have also been investigated.30 These studies focussed on 
general use of CAMs and none within a specific disease. The one Durban based study looked at 
attitude, knowledge and practices of health workers in HIV/AIDs clinics on CAM practitioners33. 
No study has been conducted in South Africa or elsewhere with regards to CAM for eczema and 
what role mainstream healthcare providers play in terms of their knowledge, awareness and their 






1.1.1.5.Problem Statement, Knowledge Gaps and Significance of this Research  
 
Considering the widespread use of CAM for atopic eczema globally, the literature has 
demonstrated that the current evidence of efficacy of commonly used alternative therapies is 
inconsistent and conflicting, with some studies reporting efficacy and others not. The literature 
has also demonstrated that there are shortcomings in the available published data. In view of this, 
it is difficult for clinicians to assess the role of specific CAMs, if any, in the management of atopic 
eczema.  
 
Although systematic reviews (SRs) of controlled trials have been undertaken on various CAMs 
assessing their current evidence of safety and efficacy, these have been found to be varied in their 
conclusions. There are several SRs undertaken for the most commonly used CAMs reported in 
the literature, namely, Chinese Herbal Medicines (CHM),12,13,34 homeopathy,10 oral herbal 
remedies including evening primrose oil (EPO) and borage oil (BO),35 probiotics 36 and certain 
dietary supplements37. However, there is no consolidated overview of these multiple SRs of CAM 
for AE. It became evident that a thorough scrutiny and analysis of the most recent of these SRs is 
needed to be able to provide objective information to busy, often sceptical allopathic practitioners 
regarding the current evidence of CAM in atopic eczema. This study sought to consolidate and 
critically evaluate all recently published SRs in order to provide evidence-based clarity to all 
practitioners treating patients for atopic eczema in light of the most current findings. 
 
Although several international cross-sectional studies have analysed the use of CAM and 
determinants of this use amongst patients, the literature and data in South Africa is lacking. 
Exploration into the extent of CAM use amongst atopic eczema patients in a local setting would 
be able to provide valuable insight into the various modalities of CAM employed by patients for 
atopic eczema and the factors influencing their use. Through this, it would be possible to provide 
new information beneficial for dermatologists, paediatricians, general practitioners, pharmacists 
as well as complementary and alternative practitioners. This information may help improve the 
understanding and manner in which HCPs consult, interact with and advise atopic eczema patients 
which turn can lead to an overall improved clinical outcome. 
 
Much of the literature to date has shown that a major driving factor for the use of CAM in atopic 
eczema is the significant apprehension amongst patients towards the use of steroids, both topical 
and oral. Steroids still remain the mainstay of treatment for atopic eczema but fear of their long 
term safety has generated a continued search for safer alternative agents. Several published studies 
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have made reference to the wide use of topical herbal creams e.g. chamomile,38, 39 licorice gel 40 
and St John’s wort41 for atopic eczema. Trials with other types of topicals have also been 
conducted including hamamelis distillate cream42 and unani formulation43 amongst others noted 
in the literature review. Certain traditional herbal medicines common in Pakistan have been 
reported to be effective for eczema44 as well as massage therapy with essential oils, although not 
in controlled trials.45 The evidence of efficacy varied amongst the various topical treatments in 
the literature. Upon sifting through the various SRs of diverse CAM therapies, it became evident 
that no SRs have been conducted for topical herbal therapies, despite many controlled clinical 
trials and despite SRs of topical herbal treatments being published for other chronic skin 
conditions like psoriasis; thus making it difficult to evaluate their efficacy. Conducting a SR on 
topical herbal extracts for atopic eczema is an imperative tool which would help analyse and 
ascertain their overall efficacy and safety and thus be able to provide clarity to the prescriber as 
well as direction steering future research on topical herbal products for AE. 
 
The literature has demonstrated the lack of knowledge amongst most healthcare practitioners on 
CAM. Details on their attitude and practices have also been clearly highlighted in many papers 
surrounding CAM use. However, these have been on general CAM use and there have no studies 
that have demonstrated norms of practice, attitudes and knowledge within the context of a specific 
disease. The widespread use of CAM in atopic eczema has been confirmed and it can be seen that 
patients have generally embraced its use, however the role and familiarity of the dermatologist, 
paediatrician, GP or pharmacist and their viewpoints and recommendations on CAM for eczema 
are thus far unexplored, both globally as well as in Africa. Investigating the knowledge, attitude 
and practices of healthcare practitioners that patients consult with for the treatment of atopic 
eczema would be beneficial in assessing their extent of knowledge of CAM, awareness of its use 
among patients as well as their ease or proactiveness in communicating with patients regarding 
CAM when necessary. Findings from this would amongst other aspects, help identify if there is a 
need for appropriate continuing education programmes or a need for implementation of CAM 
teaching in undergraduate curricula.  
 
Finding answers through the objectives set out in this study would contribute significantly to what 
is lacking in the current literature in South Africa, Africa and globally. In meeting the objectives 
of this thesis, the study aims to generate sufficient new knowledge and information essential in 
helping both patients and healthcare professionals work together in order to help improve the 




1.1.1.6. Aim and Objectives 
 
The Aim of this research was to study CAM usage in Durban, KwaZulu-Natal with the following 
objectives: 
• To collectively evaluate all published systematic reviews to date on the most popular 
CAM modalities for atopic eczema, namely, Chinese herbal medicine, homeopathy, 
herbal medicines and dietary supplements in order to provide objective information on 
their efficacy and safety in light of the most recent findings.  
• To conduct a systematic review of controlled trials with all topical herbal therapies for 
atopic eczema.  
• To conduct a cross-sectional study amongst atopic eczema patients exploring the 
demographics of CAM users, extent and determinants of CAM use. 
• To conduct a cross-sectional study surveying dermatologists, paediatricians, general 
practitioners and pharmacists exploring their knowledge, awareness of use, 
recommendations and attitude on CAM use.  
 






1.2.1. Methodology for Objective One 
 
In order to achieve Objective One as detailed in the research description, “An overview of 
Systematic Reviews”, literature searches were carried out using the following databases: 
Summon, EBSCO, PubMed, Google Scholar and Cochrane Library up to November 2013. The 
search terms used were ‘eczema/dermatitis’, ‘review’, ‘systematic review’ accompanied by the 
terms ‘Chinese herbal medicines’, ‘homeopathy’,’ herbal therapy’, ‘probiotics’, ‘evening 
primrose oil’, ‘dietary supplements’, ‘complementary medicine’, ‘alternative treatment’, 
‘adjunctive therapy’. The bibliographies of all included SRs were scanned for further relevant 
references. Only SRs of controlled clinical trials with participants of any age with eczema in peer 
reviewed journals of English origin were reviewed. This overview presents the findings from the 
most recent of these SRs.  
 
1.2.2. Methodology for Objective Two 
 
As detailed in the research description, Objective Two is a systematic review (SR) based on 
studies of controlled trials for topical herbal therapies. Although no protocol was registered with 
the Cochrane Collaboration; the leading source and gold standard for SRs, this SR was conducted 
with reference to the Cochrane Handbook for Systematic Reviews of Interventions Version 
5.1.0.46  
 
The electronic databases that were searched from inception until June 2014 were: PubMed, 
Cochrane Library, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL 
(via EBSCO), MEDLINE (via EBSCO), Proquest Health and Medical Complete. Bibliographies 
of retrieved studies were hand-searched for other relevant trials. Subsequent searches were 
conducted on additional databases, CAM-quest and GREAT.  
 
Varying search terms were used and adjusted according to the suitability for the different 
databases. Search terms were ‘atopic eczema/atopic dermatitis’ together with ‘topical herbal’, 
‘topical application’, ‘topical administration’, ‘plant extract’, ‘natural’, ‘cream’, ‘ointment’ and 




All controlled clinical trials published in English that tested a topical herbal medicine for AE in 
human patients of any age, regardless of the control intervention or randomisation, were included. 
All patients had to be clinically diagnosed with AE. Studies that were excluded were studies on 
other types of eczema (e.g. hand eczema) and where the type of eczema was not clearly classified 
(e.g. chronic eczema). Other exclusions were case reports, case series and clinical trials that were 
not conducted within a controlled environment. 
  
Two independent reviewers (Thandar, Mosam) scrutinized the titles and abstracts of the initial 
search results. Thereafter a selection of full texts was made. Any discrepancies were clarified by 
two other independent reviewers (Botha, Gray). Data from included trials were extracted and 
tabulated by one reviewer (Thandar) and checked independantly by three other reviewers  
(Mosam, Botha, Gray). Study authors were contacted where clarity was required. The risk of bias 
(ROB) in each study was assessed by three independent reviewers (Thandar, Mosam, Gray) using 
the Cochrane domain-based evaluation.  
 




A cross-sectional descriptive study design was used with the aid of interview-assisted 
questionnaires. Ethical approval for this study was obtained from the Biomedical Research and 
Ethics Committee of the University of KwaZulu-Natal (BE219/14). 
 
1.2.3.2.Study Population and Study Location 
 
Based on statistics on the number of patients with eczema seen on a monthly basis at King Edward 
VIII hospital, as well as independent private dermatological practices, the appropriate sample size 
was calculated. Using an extensively prepared questionnaire, a total of 206 patients were 
recruited. 106 patients were recruited from the outpatient dermatology clinic at King Edward VIII 
Hospital (KEH), a tertiary teaching hospital and the largest dermatology clinic in KwaZulu-Natal. 
The other 100 patients were recruited from five private dermatology practices in central Durban, 
KwaZulu-Natal. The reason for recruiting patients from both the public and private sector was to 







Using the structured questionnaire, public patients were interviewed face-to-face whereas patients 
recruited from private practices were interviewed telephonically. In the case where the patient 
was a child, the parent or primary care-giver was interviewed. A Zulu-speaking translator was 
present during all interviews with public patients as this is the main language of the Black African 
population in KwaZulu-Natal and patients attending the outpatient dermatology clinic were 
predominantly from this population group.  
Public patients were recruited over a three-month period (September 2014-November 2014) and 
private patients over a six-month period (January 2015-July 2015). The study sample included 
patients of all ages with atopic eczema. Patients all had an existing confirmed diagnosis of atopic 
eczema by a consulting dermatologist at the outpatient clinic or private practice.  
An informed written consent was obtained from public patients whereas a verbal consent was 
obtained telephonically with private patients.  
The questionnaire was initially administered to a pilot group of 10 patients. This enabled us to 
make necessary changes to questions that were ambiguous, and add appropriate questions that 
enable the easy lead- on to questions that follow.  
 
1.2.3.4.  Statistical analyses 
 
Data was analysed using Stata 13.0 SE (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP). Relationships between continuous predictors and CAM use 
were assessed using a standard t-test. One-way analysis of variance (ANOVA) was employed to 
compare means of continuous predictors across 3 or more groups. Differences in frequencies of 
categorical explanatory variables by CAM and AE were assessed using Pearson chi-square (χ2) 
test or Fishers exact test if an expected cell count contained fewer than 5 observations. A p-value 
of <0.05 was deemed statistically significant. 
 




A cross-sectional descriptive study design was implemented. Ethical approval for this study was 
obtained from the Biomedical Research and Ethics Committee of the University of KwaZulu-





Using emailed and hand-delivered questionnaires, participants were recruited to participate in this 
survey. General practitioners (GPs), dermatologists, paediatricians and pharmacists who were all 
practicing in private practice in Durban and surrounding areas (within 20km radius of Durban), 
Kwa-Zulu Natal were randomly selected using a register, professional societies’ databases and 
telephone directory for registered GPs, pharmacies, dermatologists and paediatricians. All HCPs 
had to be practicing in a private practice where they treat AE patients, however, dermatologists 
and paediatricians were also considered if they consult in the public sector. Participants were 
recruited between October 2014 and February 2015. Sample sizes were calculated based on 
population estimates in Durban and surrounding areas of each type of healthcare professional 
represented in the study and were confirmed with a biostatistician. A total of 823 healthcare 
practitioners were recruited. These included 34 dermatologists, 61 paediatricians, 570 general 





Participants were sent a direct email with a link to the questionnaire. Questionnaires were also 
hand-delivered to HCPs practicing nearby. They were asked to complete and return the 
questionnaire within 10 working days. Three reminders were sent electronically after 10, 15 and 
20 working days. Reminder telephone calls were also made to many HCPs. Where accessible, the 
researcher or research assistant approached participants directly requesting a short time for them 




Data was analysed using Stata 13.0 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP). Categorical data were summarised using frequencies and 
percentages. Association between type of HCP and attitudes, familiarity and practice using 
CAM variables were assessed using the Pearson chi-square (χ2) test and Fishers exact test if any 
cell count contained fewer than 5 expected observations. A p-value <0.05 was considered as 





1.2.5. Data Storage  
 
 All data is currently stored in a password protected file on the primary researcher’s PC. The data 
will be kept for a period of 10 years post analyses. Thereafter, it will be electronically deleted. 
Hard copies of completed surveys are currently stored in a locked cupboard in the primary 
researcher’s office and will be shredded after 10 years. 
 
1.3. STRUCTURE OF THIS DISSERTATION 
 
Chapter One outlines the background and reviews the literature, problem statement, significance 
of the study, aim and objectives of the study and the structure of the dissertation. It also describes 
the methodology that was used for data collection and data management. The methods of 
statistical analyses are also discussed in this chapter. 
 
Chapter Two consists of the first manuscript that addresses Objective One. This has been 
published in the accredited and peer-reviewed journal, South African Family Practice. The 
citation is as follows: 
Complementary Therapy in Atopic Eczema: The Latest Systematic Reviews 
Thandar Y, Botha J, Mosam A 
South African Family Practice 2014; 56(4):216-219 
http://dx.doi.org/10.1080/20786190.2014.953864  
 
Chapter Three consists of the second manuscript that addresses Objective Two. This has been 
accepted for publication in the accredited and peer-reviewed British Journal of Dermatology. The 
citation is as follows: 
Topical Herbal Medicines for Atopic Eczema: A Systematic Review of Randomised 
Controlled Trials 
Thandar Y, Gray A, Botha J, Mosam A 
British Journal of Dermatology 2016 Jul 4; doi: 10.1111/bjd.14840. [Epub ahead of print] 
 
Chapter Four consists of a third manuscript that addresses Objective Three. This has been 
submitted for publication and is currently under review in the accredited and peer-reviewed 
Health SA Gesondheid. The paper is entitled:  
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Complementary and Alternative Medicine Use amongst patients with Atopic Eczema - a 
South African Perspective 
Thandar Y, Botha J, Sartorius B, Mosam A 
Health SA Gesondheid, submitted August 2016, Manuscript number HSAG-D-16-00045 
[under review] 
 
Chapter Five consists of a fourth manuscript that addresses Objective Four. This has been 
accepted for publication in the accredited and peer-reviewed journal, South African Family 
Practice and is entitled: 
Knowledge, Attitude and Practices of South African Healthcare Professionals towards 
Complementary and Alternative Medicine Use for Atopic Eczema - A Descriptive Survey 
Thandar Y, Botha J, Sartorius B, Mosam A 
South African Family Practice, 2016 Sept 26; Manuscript number SAFPJ-2016-0058;  
doi: 10.1080/20786190.2016.1248146 [in press] 
 
Chapter Six consists of the synthesis of the study and the conclusion. This chapter also includes 




1.4. LITERATURE REVIEW 
 
1.4.1. CAM and its Global Prevalence  
 
A uniform or consistent definition of complementary and alternative medicine does not exist 
across the literature. However, according to the National Centre of Complementary and 
Alternative Medicine (NCCAM), complementary and alternative medicine (CAM) is defined as 
“a group of diverse medical and healthcare systems, practices, and products that are not generally 
considered part of conventional medicine”. "Complementary medicine" refers to use of CAM 
together with conventional medicine and "Alternative medicine" refers to use of CAM in place of 
conventional medicine.47 Many of the techniques used as CAM therapy are the subject of 
controversy and have not been validated by controlled studies. They are also regarded as having 
no scientific basis for which no effective or diagnostic reliability has been demonstrated by 
scientific methods.48 The use of CAM however, is recognised as abundant around the world and 
is shown to be increasing. The World Health Organization estimates that 65%-80% of the World’s 
population uses Complementary and Traditional Medicine as their primary form of  
healthcare.49, 50 
 
According to the 2007 National Health and Statistics report in the United States, 4 out of 10 adults 
had used CAM therapy in the past 12 months. In this report, data from a 2007 National Health 
Interview Survey (NHIS) revealed that approximately one in nine children used CAM therapy in 
the last 12 months preceding the survey. Some of the reasons for choosing CAM include the relief 
of symptoms associated with chronic, even terminal illnesses and the side effects of conventional 
medicines. Other reasons included were a holistic health philosophy and wanting greater control 
of one’s own health51. 
 
According to the European Federation of Complementary and Alternative Medicine (UFCAM), 
CAM is being increasingly used by citizens across Europe as a means of maintaining their health 
and for treating ill-health.52 In 2012, Zuzak et al. published data which revealed that 56% of the 
European population had used CAM in the last year and the prevalence of CAM use by children 
in Europe was 52%.53 An Australian survey in 1992/1993 found that 48,5% of the population used 
at least one non-medically prescribed alternative therapy modality and in a 2006 study it was 




A South African study conducted by Peltzer in 2009 reviewing all published and unpublished 
research investigating the prevalence of traditional medicine (TM) and complementary and 
alternative medicine (CAM) in the general population, showed a decline in TM use but an increase 
in the range of CAM use over the past 13 years. Local population-based and health facility-based 
surveys seem to indicate that TM and CAM use still plays an important role in healthcare delivery 
in South Africa, covering a wide range of conditions from chronic conditions, acute conditions, 
complex supernatural or psychosocial problems, generalised pain, HIV and other sexually 
transmitted infections. A lack of data about CAM use in the varying conditions was reported.24 
 
1.4.2. CAM use in Dermatology 
 
An extensive literature search revealed a number of studies on the growing prevalence of CAM 
amongst patients with dermatological conditions. In a study showing trends of CAM use in the 
United States, 6.7% of patients who reported having skin problems over the last 12 months, used 
alternative therapy for their condition and 2.2% visited an alternative practitioner for their skin 
condition.56 Another study showing an overview on the use of CAM for skin diseases in the 
United States reported that, in a 2009 study, 49.4% of patients with skin problems have used CAM 
within the previous year and 6% had used it specifically for their skin disease.57 
 
According to a 2007 review on the use of CAM in skin diseases by Magin and Adams, 14% of 
patients attending a UK National Health Service CAM clinic, did so for skin conditions and 16% 
of British dermatological outpatients used CAM for their skin disease.58 Another UK based study 
conducted in Leeds and South Wales and published in 2005, investigated CAM in a large 
population of outpatients with general dermatological conditions and found that of the 39% of 
patients that used CAM in Leeds, 45% of them used it for dermatological conditions and of the 
34% using CAM in South Wales, 50% was for dermatological conditions. This study also 
revealed that the majority of CAM use was for treatment of eczema and psoriasis, and herbal 
medicine and homeopathy were the most popular complementary therapies used.59 In an Israeli 
study, 6.9% of the 19% of general practice patients who used CAM, did so for their skin disease.58  
 
The types of skin diseases where CAM use has been documented are vast and include acne, 
psoriasis, certain skin malignancies and atopic eczema.60 In a cross-sectional South African-based 
study conducted in 2000-2001 in an Indian community in Chatsworth which explored the 
prevalence and patterns of CAM usage for general ailments, the prevalence was 38.5%. Of this, 
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16.9% of usage was for skin disorders.22 From the literature, there have been no studies done in 
South Africa investigating the use of CAM in skin diseases in particular. 
 
1.4.3. CAM use by Patients with Atopic Eczema 
 
Several international studies have explored the use of CAM in dermatitis, both allergic contact as 
well as atopic dermatitis/eczema. Once such study in Denmark conducted between 2000 and 2003 
reviewed the use of CAM in patients with allergic contact dermatitis. In this particular study it 
was found that 40% of patients used CAM (predominantly in combination with conventional 
treatment), 29% had visited an alternate practitioner, women were more frequent users of CAM 
and patients from urban/rural districts were more frequent users than patients from the capital city 
area. It was also noted that frequent eczema eruptions, hand eczema, long duration of the disease 
and work-related problems were positively associated with the use of CAM.17 This is in keeping 
with other studies that have also positively related the use of CAM with disease severity and 
duration, rather than the type of dermatological condition.61 The study by Noiesen et al. concluded 
that the use of CAM was not an alternative to conventional medicine, but a supplement, or 
complementary.17 
 
In a European study describing the epidemiological characteristics and determinants of the use of 
CAM, it was reported that 30-50% of patients with allergies have had experiences with CAM. 
Users of CAM tend to be younger women with a higher educational background. Users and non-
users of CAM differed in their psychomedical characteristics, such as health locus of control or 
health-related quality of life. Although a large number of different CAM modalities are provided, 
the techniques which account for the majority of use were acupuncture, homoeopathy, herbalism, 
bioresonance and autologous blood injection. In Germany, the use of CAM was associated with 
considerable costs despite its limited evidence of efficacy.62 Although this study focussed on 
allergies in general, it provides a good overview of the demographic profile of CAM users.  
 
Of the studies qualifying and quantifying the use of CAM in children with atopic eczema, a 2002 
study conducted in a teaching hospital in Leicester in the United Kingdom found that 63% of the 
subjects had used or intended to use CAM for their eczema. There was a strong association 
between the use of CAM and ethnicity, the majority of patients being from the Indian 
subcontinent. The most popular CAM modalities used were Chinese herbal medicine (41%), 
followed by herbal medicines (41%) and homoeopathy (35%). Half of the CAM users used it on 
the recommendation of family and friends with skin disease, 37% from family or friends without 
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skin disease and 6% each from health professionals, the media and the internet. 54% used CAM 
because conventional medicine was not working and 17% used CAM because they were 
concerned about the side effects of conventional medicines. While 39% of all patients felt that 
CAM was safer than conventional medicines, only 14% felt it was more efficacious. More than 
half of the patients were happy to combine CAM treatments with their conventional treatment 
and 66% of patients felt that CAM should be available from the National Health Service. 35% of 
patients using CAM felt that their eczema had improved while 53% reported that it remained 
unchanged 9. The results regarding the use of the CAM modality adopted and its impact on the 
eczema was based on patients’ responses and no validated assessment on disease severity or 
health-related quality of life over time was assessed. Hence, the overall impact of CAM on the 
disease could not be assessed.  
 
Another cross-sectional study carried out amongst paediatric patients with atopic eczema within 
a university teaching hospital in Dublin, Ireland was published in 2007. This study assessed the 
prevalence of CAM and the varying factors associated with its use. Duration of treatment, reasons 
for trying CAM, approximate cost and success of treatment, duration of childhood eczema, and 
hospital admission due to eczema were assessed. Of the patients’ assessed, 42.5% had used either 
one type or more than one type of CAM modality. Herbal remedies (41%) and homoeopathy 
(23.5%) were most frequently used. The most commonly cited reasons for trying alternative 
therapies were a recommendation from others (47%), a fear of steroid side effects (26.4%) and 
dissatisfaction of conventional treatment (17.6%). Most treatments were reported to show no 
improvement (57.7%) and 44.1% reported some improvement with CAM use, mostly a reduction 
in itching. In almost 10% of patients, deterioration was reported. An average cost of treatment 
with CAM was estimated around 322 Euros. The study also demonstrated that the overall severity 
of eczema in both users and non-users were similar.8  
 
Other studies investigating the extent of CAM use amongst atopic eczema patients were 
conducted in Korea where it was found that 69% of patients used CAM,19 Norway (51%)21 and 
the US (50%).20  
 
Many of the findings in the study in Dublin were similar to the study carried out in Leicester 
however, the majority of CAM users in Dublin were indigenous Irish which is a contrast to the 
majority ethnic origin (and of Indian decent) in the Leicester study. In both studies, a disease 
severity score was not performed and severity was estimated based on the patients’ response on 
the questionnaire and in the number of admissions to hospital, as in the latter study; thus making 
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the evidence of CAM’s efficacy subjective. Both studies were also unable to determine whether 
those with more severe disease were more likely to experiment with CAM. The population in 
these studies were predominantly of low socio-economic status (as in the Dublin study) or from 
an ethnic minority (as in the Leicester study). Other research has demonstrated that children with 
higher socio-economic status are more affected with atopic eczema than children from poorer 
families.63 
 
Considering that no South African studies have been conducted in this field, we are thus unaware 
if differences lie between users of CAM from different socio-economic backgrounds and different 
racial groups. The South African environment, with its multiracial, multi-ethnic and diverse 
socio-economic backgrounds provides an ideal backdrop to determine whether such variables 
influence the use of CAM. Furthermore, no South African based studies have been conducted 
describing trends of use of CAM within the country’s demographic context. There are also no 
published data providing evidence of the varying types of alternative medicines patients are 
currently employing for their eczema. 
 
1.4.4. The Most Common CAM modalities used by Patients with Atopic Eczema  
 
From the literature, it was found that the most commonly reported CAM modalities used for 
atopic eczema were Chinese herbal medicine (41%), followed by herbal medicines (41%) and 
homoeopathy (35%) which was reported in the Leicester study9 and herbal medicines (41%) and 
homoeopathy (23.5%) in a study in Dublin, Ireland.8 A study in Korea reported frequent use of 
Oriental medicines (26%), and bath therapy (21%)19. Vitamins and herbal creams were commonly 
used in a US based study.20 Among patients in Norway, herbal medicines (19%) and homeopathy 
(34%) were reportedly commonly used.21 This study, together with the Korean based study also 
documented a fairly high usage of health food preparations, 18% and 17% respectively. 
 
As homeopathy was commonly reported to be favoured amongst patients exploring CAM in 
several studies, a literature review of this modality was undertaken in interest of determining its 
evidence-based effect for atopic eczema. It was found that the literature demonstrated a 
conflicting evidence of efficacy from the trials that were reported in homeopathy.  
 
Witt et al. have reported that one in five children visiting a homoeopathic physician is suffering 
from atopic eczema.14 In a multicentre cohort study in Germany and Switzerland investigating 
homoepathic practices, it was identified that atopic eczema in children was amongst the most 
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frequent diagnoses together with other chronic diseases. This study assessed disease severity and 
quality of life at intervals during a 2 year period and the results showed that patient and physician 
assessment of disease severity and quality of life demonstrated marked and sustained 
improvements following a homoeopathic treatment period. This improvement was more 
pronounced in younger patients and those with greater disease severity. In this study, patients 
were allowed to use conventional therapies in addition to homoeopathic treatment during the 
study period and thus the observed improvement cannot be attributed to homoeopathic treatment 
alone.11 As the results of this study was not only demonstrative of atopic eczema but included 
other chronic illnesses like allergic rhinitis and headache in adults and children, a further study 
conducted by Witt et al. which had a clear disease-specific and children-specific approach, 
focussed on the comparison of homoeopathic versus conventional treatment in children with 
atopic eczema. The outcome measures was the Scoring Atopic Dermatitis (SCORAD), at 6 and 
12 months respectively as well as quality of life in parents and children, use of conventional 
medicine, disease-related costs, response rates and safety of treatment at 6 and 12 months. There 
were no significant differences as shown between the groups for the SCORAD at 6 and 12 months 
and quality of life was also comparable between the groups. However, costs were higher in the 
homoeopathic group than in the conventional group.14 
 
For homeopathy as an example, the two studies by Witt et al. have shown conflicting results thus 
making any conclusions about efficacy impossible.11, 14 Reports of efficacy of many of the other 
popular alternative therapies are also contradictory64 and the vast available literature and 
published data are filled with shortcomings making it difficult for doctors to evaluate whether or 
not there is any role for them in the management of eczema.65 
 
To assess their evidence, systematic reviews (SR) of controlled clinical trials, which are critical 
to any evidence based practice of medicine, have been undertaken for CHM,12, 13, 34 homeopathy,10 
oral herbal remedies including evening primrose oil (EPO), borage oil (BO),35 probiotics 36 and 
certain dietary supplements.37 On assessing these SRs, many of them were varied in their 
conclusions. It became evident that a thorough scrutiny and analysis of these SRs is needed and 
is imperative to be able to provide objective information to busy, often sceptical allopathic 
practitioners regarding the current evidence of CAM in AE. 
 
Several published studies have made reference to the wide use of topical herbal creams e.g. 
chamomile 38, 39, licorice gel 40 and St John’s wort 41 for atopic eczema. Trials with other types of 
topicals have also been conducted including hamamelis distillate cream42 and unani formulation.43 
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Although not tested in clinical trials, some traditional herbal medicines common in the Pakistan 
have also been reported to be effective for eczema.44 Massage therapy with essential oils have 
also been explored for atopic eczema.45 Evidence of efficacy varies amongst the topical treatments 
and only few have been tested in controlled trials. Upon sifting through the various SRs of the 
diverse CAM therapies, it became evident that no SRs have been conducted for topical herbal 
therapies thus making it difficult to evaluate their efficacy. A SR on all controlled trials with 
topical CAM treatments will undoubtedly provide conclusions which are currently lacking in the 
literature with regards to their efficacy and safety in atopic eczema. 
 
1.4.5. Patients and the Determinants for the Use of CAM 
 
It is imperative from both academic and applied perspectives to understand why such substantial 
numbers of people use CAM. Many reasons have already been cited in the literature. Frequently 
cited reasons was the dissatisfaction with the therapeutic results from conventional medicines, the 
concern about the side effects of conventional medicines particularly the steroids, and the 
perceived safety of CAM compared to conventional medicines. 8, 9 Some used CAM mainly on a 
recommendation from others.8, 9, 19  
 
A systematic review of beliefs involved in the use of CAM was collated and synthesised in 2007 
by Bishop et al. The evidence suggests that CAM users want to participate in treatment decisions, 
are likely to have active coping styles and might believe that they can control their health. They 
value non-toxic, holistic approaches to health and hold ‘postmodern belief systems’ while 
viewing themselves as unconventional and spiritual. CAM users also tend to believe that 
psychological and lifestyle factors are important in the development of illness. There is evidence 
that different variables are associated with CAM use in groups of CAM users that differ according 
to different illness groups.66 It is however difficult to determine with any confidence whether pro-
CAM beliefs are held prior to and influence CAM use or are actually a result of CAM experiences.  
 
There is no literature available within the South African context that has investigated patients 
motivations for CAM use. Considering that local studies in this field are lacking and given the 
popularity of CAM, a South African based study would help to understand why people use CAM 
and may generate factors that can predict CAM use. Such information is of interest to 
dermatologists and other practitioners, helping them to understand better their patients’ use and 
motivations for using CAM and possibly to improve practitioner-patient communication 
concerning both conventional medicine and CAM. Also, certain aspects of CAM use that are 
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valued by patients such as holistic and patient-centred care may be incorporated when treating 
with conventional medicine. An understanding of patients’ beliefs may help to guide practitioners 
in educating their patients with regards to their perceptions that all CAMs are “natural” and “safe” 
and steroids are harmful. 
 
1.4.6. CAM and the Healthcare Practitioner  
 
Despite the dramatic increase in the general use of CAM, whether for an existing illness or for 
the purpose of prevention or maintenance of health, the extent to which patients disclose their use 
of any alternative therapy to their medical practitioner remains low. This was seen in a follow-up 
national survey by Eisenberg et al. which revealed that less than 40% of the alternative therapies 
used were disclosed to a physician in both 1990 and 1997.56 The literature has also demonstrated 
that patients often do not inform their dermatologist about their use of CAM and the 
dermatologists’ ability to predict CAM use in their patients has been found to be poor.25 The 
doctor’s knowledge about a patient’s use of CAM may lead to a better understanding of the 
patient’s attitude to the disease and subsequently help to achieve better patient compliance.17 
 
According to Zhang et al., there exists barriers in communication between patient and physician 
which include reluctance to disclose CAM use, physicians not asking about CAM use and patients 
perceiving that their physicians are unwilling to discuss CAM therapies.67 In a Netherlands based 
study amongst paediatricians it was found that 62% of paediatricians seldom ask parents of 
patients about CAM use.28 It has also been reported that physicians generally underestimate the 
prevalence of CAM use among their patients.68 This confirms a definite discrepancy between the 
patients’ use and the familiarity of the healthcare practitioner with CAM. These practices of the 
healthcare practitioner relates directly to their attitudes and knowledge of CAM.  
 
A 2010 Qatar based study exploring the attitudes, knowledge and practice of general practitioners 
towards CAM, revealed that 39.1% of doctors reported poor knowledge about CAM. It is 
interesting to note that 83.8% described their attitude to CAM as welcoming and 97.5% were 
interested to learn more about it, fewer (30.1%) had practised it before or asked patients' about 
their use of CAM (34.8%). Their own lack of knowledge and training in CAM was seen as a 
barrier to its use by 60.0% of the general practitioners.26  
 
Several other studies have also demonstrated a positive attitude from the healthcare practitioner 
towards CAM. In a study amongst primary care providers at a Family Medicine Clinic in West 
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Texas, 75% believed that incorporating CAM into general practice would be positive and 70% 
believed that the institution should offer proven CAM therapies to patients.31 Saudi Arabian 
primary healthcare physicians generally showed a positive attitude towards CAM and believed 
that it would lead to a better patient outcome but demonstrated reluctance to discuss with patients 
or refer patients. This may be due to a lack of knowledge as 85% agreed that physicians should 
have knowledge about CAM.69 This is consistent with many other studies including a Netherlands 
based study where more than 50% of paediatricians admitted that they had little knowledge of 
CAM.28 Also, in a study in Brisbane, Australia, pharmacists have confirmed that although there 
may be potential benefits for patients, a lack of knowledge about safety were definite barriers to 
their recommendation. However, despite their lack of knowledge, they often recommend CAM 
alongside conventional medication as part of their pharmacy protocol.27 In an exploratory survey 
in California assessing doctors attitudes towards their patients use of CAM, and their willingness 
to prescribe and enquire about CAM, 61% did not feel sufficiently knowledgeable about CAMs’ 
efficacy or safety and 81% would like to receive more education.70 
 
From the literature review, it can be seen that most healthcare practitioners acknowledge their 
lack of knowledge on CAM and want to be more informed about safety and efficacy of commonly 
used CAM products. Many have recommended that CAM should be taught in the undergraduate 
study and included into medical and pharmacy curricula.27, 32, 71 These findings raise important 
issues for medical education and patient care. The scenario between high acceptance levels with 
regards to CAM and poor knowledge can be viewed as critical, demanding urgent intervention to 
bridge the gap.72 
 
On the contrary, there are some studies that have demonstrated scepticism and uncertainty about 
the value of CAM. One distinct study conducted in Bristol, UK explored views of academic 
doctors who have a dual academic and clinical role. The majority were doubtful with the reasons 
being related to their perspective on the scientific evidence base. Some were more open to it as a 
result of personal experience shaping their views. Despite this, most acknowledged that better 
doctor-patient communication and patient disclosure is required. However, their views on 
educating themselves on CAM were varied.30  
 
Only one similar study was found in South Africa. Considering that traditional, complementary 
and alternative medicines (TCAM) are commonly reported to be used amongst HIV and AIDS 
patients, the HIV/AIDS clinics in Durban were the selected backdrop. The study involved all 
categories of healthcare workers in these clinics, including doctors, nurses, counsellors, 
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psychologists and social workers, and examined their knowledge, attitudes and practices 
regarding various TCAM professions (and not select medicines). The results demonstrated a lack 
of basic knowledge amongst the majority on TCAM.33 
 
The studies in this literature review have demonstrated attitudes, knowledge and practices of 
various healthcare professionals on the general use of CAM. This provides a good insight, 
however, no published work has been found on the knowledge, attitudes and practices of 
healthcare professionals on CAM use when treating patients with eczema. The widespread use of 
CAM in atopic eczema has been confirmed, however the role and familiarity of the GP, 
dermatologist, paediatrician or pharmacist and their viewpoints and recommendations on CAM 
for atopic eczema are currently unexplored.  
 
Considering that CAM and conventional medicine are often used together,17, 58 the potential for 
confusion in attribution of therapeutic benefits, adverse effects and drug interactions is clear as 
well as the potential for non-compliance with prescribed therapy. An appreciation by physicians 
of when and why their patients with skin disease may be using CAM therapies is essential.58 
Dermatologists, paediatricians and general practitioners need to be conversant with common 
CAM therapies and their influence on the overall clinical outcome of the patient. Enquiries with 
regards to alternative medicine use in dermatology patients is essential given that most alternative 
therapies are subject to minimal regulation and may give rise to side effects.8 Since many CAMs 
are unregulated and easily accessible, pharmacists are often the very first to be consulted on their 
usage by patients with eczema. Also, information from pharmacists would help assess what CAM 





2. CHAPTER TWO 
 
2.1. MANUSCRIPT ONE (PUBLISHED) 
 
Complementary Therapy in Atopic Eczema: The Latest Systematic Reviews 
Thandar Y, Botha J, Mosam A 
South African Family Practice 2014; 56(4):216-219 
http://dx.doi.org/10.1080/20786190.2014.953864  
 
The contents of this chapter is in the form of a published paper. This paper has met Objective one 
of this thesis.  
 
From the literature review, it was highlighted that the most frequently explored common 
modalities for atopic eczema in various international studies were: Chinese herbal medicines, 
homeopathy, herbal medicines and dietary supplements.  
 
Due to conflicting evidence of efficacy in many papers, this study investigated and collated the 
findings from the most recently published systematic reviews in order to determine objective 
information on their efficacy and safety. 
 
In so doing, the results from this study are able to provide practitioners with a comprehensive and 















2.2. LINK BETWEEN MANUSCRIPT ONE AND MANUSCRIPT TWO 
 
On investigating the current status of efficacy and safety of frequently used CAMs for atopic 
eczema as per Manuscript One:   
Complementary Therapy in Atopic Eczema: The Latest Systematic Reviews 
Thandar Y, Botha J, Mosam A, South African Family Practice 2014; 56(4):216-219 
http://dx.doi.org/10.1080/20786190.2014.953864; it became evident in the literature that 
systematic reviews which are critical in providing answers or verdicts on as yet unresolved or 
variable data, have only been published for oral CAMs. 
 
In studies qualifying and quantifying the use of CAM, topical herbal remedies are continually 
being sort as ‘safer’ alternatives to the much feared topical corticosteroids which still remain the 
gold standard for the management of atopic eczema. An extensive literature search revealed that 
many topical herbal preparations have been tested for atopic eczema; however not all have been 
controlled clinical trials. Also, there have been no systematic reviews published on any topical 
herbal remedies for atopic eczema; despite their popularity and despite the desperate search for 
suitable safer alternative topicals. Although systematic reviews of topical herbal medicines have 
previously been published for other common skin diseases like psoriasis, this research had 
identified a distinct gap in the literature for atopic eczema. The lack of evidence based information 
to assist clinicians in making informed choices and the ability to highlight areas where further 
research may be warranted is what spurred on the second objective of this research. 
 
This research in the form of Manuscript Two which has been published has bridged the gap in 
knowledge and has provided the conclusions on the current status of efficacy and safety of topical 
herbal remedies tested in controlled clinical trials for atopic eczema which were previously 
lacking. This was done through a critical and thorough reassessment of all relevant trials 
published, in the form of a systematic review.  
 
The systematic review has been accepted for publication in the British Journal of Dermatology 
in July 2016. It is currently published online and can be accessed as follows:  
Topical Herbal Medicines for Atopic Eczema: A Systematic Review of Randomised 
Controlled Trials  
Thandar Y, Gray A, Botha J, Mosam A  




3. CHAPTER THREE 
 
3.1. MANUSCRIPT TWO (PUBLISHED) 
 
Topical Herbal Medicines for Atopic Eczema: A Systematic Review of Randomised 
Controlled Trials 
Thandar Y, Gray A, Botha J, Mosam A 
British Journal of Dermatology 2016 Jul 4; doi: 10.1111/bjd.14840. [Epub ahead of print] 
http://onlinelibrary.wiley.com/doi/10.1111/bjd.14840/full  
 
The contents of this chapter in the form of a published paper online (print version to follow) has 
met Objective Two of this thesis. It presents a collation and critical analysis in the form of a 
systematic review of multiple controlled trials on topical herbal medicines for treating atopic 
eczema. This research has helped establish conclusions on efficacy of these topical agents and 
has helped open avenues for future research by identifying investigating agents in trials that have 
shown promising results. 
 
In addition, an author’s video, as was requested by the editor of the British Journal of 
Dermatology (Appendix 15), higlighting the reason for the study, methodology, main findings 
and its relevence to dermatologists and their patients with atopic eczema, was produced. This 
video recording can viewed using the following link: 
https://drive.google.com/file/d/0BzpWegUfKOmmaThFbGpVSUxBckk/view?usp=drivesdk  
(Also available on CD/SD Card attached:  
Filename: BJD Video-Topical Herbal Medicines for Atopic Eczema- A Systematic Review of 





































































































Fig 1 Flow chart showing selection process of controlled clinical trials of 





Fig 2 Risk of bias graph, presented as percentages 





3.2. LINK BETWEEN MANUSCRIPTS ONE AND TWO, AND 
MANUSCRIPT THREE 
 
Stemming from the literature review, this thesis was able to ascertain common CAM modalities 
used amongst patients for atopic eczema in many countries including Ireland, United Kingdom, 
Korea, United States and Norway. These common CAM modalities have been critically reviewed 
in both Manuscript One:  
Complementary Therapy in Atopic Eczema: The Latest Systematic Reviews 
Thandar Y, Botha J, Mosam A, South African Family Practice 2014; 56(4):216-219 
http://dx.doi.org/10.1080/20786190.2014.953864  
and Manuscript Two:  
Topical Herbal Medicines for Atopic Eczema: A Systematic Review of Randomised 
Controlled Trials  
Thandar Y, Gray A, Botha J, Mosam A  
British Journal of Dermatology 2016 Jul 4; doi: 10.1111/bjd.14840. [Epub ahead of print] 
http://onlinelibrary.wiley.com/doi/10.1111/bjd.14840/full.  
Both of these published reviews have provided clarity on the efficacy and safety of these popular 
identified CAMs, with Manuscript Two bridging a gap in knowledge in the literature.  
 
The studies in Ireland, United Kingdom, Korea, United States and Norway have all reported fair 
and extensive use of CAM ranging from 43%-69% amongst their atopic eczema patients together 
with reasons and motivations for their use. Very little research has been done in South Africa 
(SA) regarding the use of CAM. A prevalence study of traditional medicine (TM) and CAM in 
the general SA population, showed declines in TM-use but increased CAM use over 13 years. 
Population and health facility-based surveys indicated that both play important roles in SA 
healthcare delivery, however, lack of data about the extent of CAM use in varying conditions was 
reported.14 Other SA studies highlighting CAMs’ popularity were amongst an Indian population15 
and in HIV patients.16  
 
A systematic review (SR) of epidemiological studies, revealed an increasing prevalence of atopic 
eczema in Africa with approximate doubling of lifetime prevalence in SA.2 Despite this, and 
considering the global hype regarding CAM, the literature revealed no African studies that 
explored CAM use in atopic eczema. Manuscript Three of this research addresses this distinct 
lack in the literature and explores the extent of CAM use among a large group of South African 
atopic eczema patients with details about prevalence, extent, types utilized, and the influence of 
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demographic factors on CAM use in atopic eczema. This manuscript is the first African study to 
provide such information, yielding new insights beneficial to dermatologists, paediatricians, 
general practitioners (GPs), pharmacists and CAM practitioners.   
Manuscript Three is entitled: 
Complementary and Alternative Medicine Use among Patients with Atopic Eczema – A 
South African Perspective  
Thandar Y, Botha J, Sartorius B, Mosam A 
Health SA Gesondheid. Submitted 31 August 2016. 




4. CHAPTER FOUR 
 
4.1. MANUSCRIPT THREE (SUBMITTED FOR PUBLICATION AND 
UNDER REVIEW) 
 
Complementary and Alternative Medicine Use among Patients with Atopic Eczema 
– A South African Perspective  
Thandar Y, Botha J, Sartorius B, Mosam A 
Health SA Gesondheid. Submitted 31 August 2016. 
Manuscript number HSAG-S-16-00045 [under review] 
 
The contents of this chapter presented in the form of a manuscript, submitted for publication and 
currently under review in the accredited Health SA Gesondheid, has met Objective Three of this 
research. Here, the findings from the surveys and interviews amongst patients suffering from 
atopic eczema and attending both public and private facilities for treatment are presented.  
 
This manuscript provides a detailed analyses of the questions that were asked to patients. This 
paper has addressed previously unanswered questions regarding the extent of CAM use amongst 
patients with atopic eczema in Durban, KZN. It has also highlighted the various modalities of 
CAM that patients in South Africa have tried or are currently using as well as an indication of 
adherence to treatments prescribed. Reasons, motivations and communication with the healthcare 
practitioner have also been addressed.  
 









































4.2. LINK BETWEEN MANUSCRIPT THREE AND MANUSCRIPT FOUR 
 
Manuscript Three: Complementary and Alternative Medicine Use among Patients with 
Atopic Eczema – A South African Perspective,  
Thandar Y, Botha J, Sartorius B, Mosam A,  
Health SA Gesondheid. Manuscript number HSAG-S-16-00045 [under review];  
has identified an extensive (66%) CAM use amongst atopic eczema patients in a South African 
setting. It is evident from this research that the majority of patients have not disclosed CAM use 
to their dermatologist (59%). About half (48%) of the patients said they were not questioned about 
CAM use by their dermatologist. 
 
Given the prevalence of its use in atopic eczema, most healthcare professionals treating patients 
for atopic eczema would encounter patients using some form of CAM. Previous studies have 
reported that healthcare professionals underestimate the use of CAM in their patients.73 This is 
likely due to lack of communication between the HCP and the patient which is evident in our 
findings in Manuscript Three in which almost half of those reporting non-disclosure said that they 
were ‘not asked’. The balance of those that reported non-disclosure felt that ‘it was not necessary 
for their dermatologist to know what other medication they are using’. 
 
These findings pose a huge risk as it affects compliance which in turn affects the overall disease 
course and outcome from prescribed treatment. It also reflects lack of assurance and trust on the 
part of the patient towards the HCP. As patients are not necessarily informed regarding the efficacy 
and safety of many of these CAMs, it is the HCP’s role to be knowledgeable about the commonly 
used CAM and be proactive in initiating discussions with patients. It has been reported that the 
degree to which HCPs are proactive in enquiring about CAM is largely influenced by their attitude 
toward them.73 It is clear that patients have generally embraced CAM, but the uncertainty about the 
level of knowledge that HCPs have to advise patients, their attitudes and standard practices 
regarding CAM is what prompted the study which is presented in Manuscript Four.  
Manuscript Four has been accepted for publication in the accredited and peer-reviewed South 
African Family Practice and is entitled:  
Knowledge, Attitude and Practices of South African Healthcare Professionals towards 
Complementary and Alternative Medicine Use for Atopic Eczema - A Descriptive Survey 
Thandar Y, Botha J, Sartorius B, Mosam A  
South African Family Practice, 2016 Sept 26; Manuscript number SAFPJ-2016-0058;  
doi: 10.1080/20786190.2016.1248146 [in press]  
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5. CHAPTER FIVE 
 
5.1. MANUSCRIPT FOUR (IN PRESS) 
 
Knowledge, Attitude and Practices of South African Healthcare Professionals 
towards Complementary and Alternative Medicine Use for Atopic Eczema - A 
Descriptive Survey. 
Thandar Y, Botha J, Sartorius B, Mosam A 
South African Family Practice, 2016 Sept 26; Manuscript number SAFPJ-2016-0058;  
doi: 10.1080/20786190.2016.1248146 [in press] 
 
This chapter which has addressed Objective Four of this thesis, examines the knowledge, attitude 
and practices of HCPs towards CAM in atopic eczema in a South African context. Several 
international studies have explored knowledge, attitude and practices amongst general 
practitioners (GPs), physicians, pharmacists, paediatricians, academic doctors and other 
healthcare workers towards CAM; 6-11 however these studies focussed on general CAM use and 
none within the context of a specific disease. There were no published studies conducted in SA 
or elsewhere investigating HCPs’ knowledge, attitudes and norms of practice with regards to 
CAM for AE.  
 
Given the extensive use among SA patients with AE,12 the views and rationales among SA HCPs 
treating patients with AE is what was investigated in this paper. Also, considering that the levels 
of knowledge, views and attitudes may vary between HCP groups, this research has taken all 
mainstream HCPs that treat patients for eczema into account, namely; dermatologists, 
paediatricians, general practitioners and pharmacists. 
 




























6. CHAPTER SIX 
 
6.1. SYNTHESIS AND CONCLUSION 
 
The synthesis consolidates this study’s predominant findings. The limitations of the study and 
recommendations are also discussed at the end of this chapter.  
 
Taking into consideration the increase in prevalence of atopic eczema in South Africa over the 
last decade3 and in light of the numerous reports on extensive CAM use for skin conditions, 
especially atopic eczema, many questions surrounding CAM use amongst local atopic eczema 
patients were prior to this study, unanswered. This research provides a synopsis on the use of 
CAM for atopic eczema in Durban, Kwa-Zulu Natal. Apart from providing a perspective on the 
trends of CAM use amongst patients, the synthesis discusses the predominant findings 
surrounding the perspectives of healthcare professionals towards CAM for atopic eczema. The 
current study has further contributed to the literature by adding results from its original systematic 
review on topical CAM and has provided clarity from findings of previously published systematic 
reviews on oral CAM. Three papers have been published from this thesis in accredited and peer-
reviewed journals and one manuscript is currently under review for publication in another 
accredited and peer-reviewed journal.  
 
The interest in complementary and alternative medicines has increased dramatically over the past 
decade. Daily, patients are spending large amounts of money on CAM, usually from their own 
pockets as most medical aid companies do not cover these treatments. This in itself reflects the 
general positivity and acceptance of CAM by the public and indicates that some of these 
treatments may provide benefits which outweigh their costs.74 The findings from this study is 
consistent with others in terms of the general embracement of CAM, whereby an overwhelming 
number of patients (66%) are currently using or have tried CAM for their atopic eczema; and 
although subjective, almost half (48%) reported “some improvement” to “definite improvement”. 
 
Despite this successful and booming commercial market, CAM use still remains controversial 
among healthcare professionals as the debate surrounding its scientific and clinical evidence base 
remains unproven in many modalities. The present study reflected that close to 90% of all 
healthcare professionals interviewed felt that CAM should be subjected to more scientific testing. 
Regardless of the attraction that CAM has for patients and the attention given to it by the media, 
information in the literature proving their efficacy and safety was inconclusive. It was thus among 
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the objectives of this current study to provide clarity on what the current evidence is with regards 
to popular oral CAMs and topical CAMs studied for atopic eczema. This was accomplished by 
investigating and critiquing the clinical effectiveness of specific and commonly used oral CAMs 
for atopic eczema in the form of an overview of the many published systematic reviews. The 
thesis also contributed to academia globally by bridging a gap in the literature and successfully 
completing and publishing the very first systematic review on topical herbal medicines for atopic 
eczema; thereby providing answers to topical herbal remedies for the disease.  
 
As an outcome from Objective One, the research identified inconclusive evidence of efficacy and 
safety with the selected frequently used oral CAMs. It was found that homeopathy failed to show 
any treatment effect whereas further studies are warranted with some therapies (Chinese Herbal 
Medicine, certain probiotic strains and fish oil). It was also noted that further studies of evening 
primrose oil and borage oil are difficult to justify as the results from these trials did not favour 
these oils over placebo and the narrow confidence intervals between active and placebo treatments 
exclude the possibility of any clinical useful difference. These results are presented in Manuscript 
One and published in South African Family Practice. The results from this overview are able to 
provide evidence-based clarity to all practitioners treating patients for atopic eczema in light of 
the most current findings in the literature.  
 
Stemming from Objective Two, as presented in Chapter Three of this thesis and published in the 
British Journal of Dermatology, is the first systematic review on topical herbal extracts for atopic 
eczema. These findings have helped analyse and ascertain the overall efficacy and safety of 
various topical preparations which was lacking in the literature, thus providing clarity to the 
prescriber as well as directions for future research on topical herbal products for atopic eczema. 
The systematic review concluded that there was insufficient evidence of efficacy for all the topical 
herbal medicines explored in the systemic review. However, with the glimmer of hope in studies 
with both positive results and a low risk of bias across all domains, the systematic review was 
able to determine specific CAMs namely, licorice gel and Hypericum perforatum; where future 
research is warranted.  
 
The thesis further examined the use and views amongst patients suffering from atopic eczema and 
also explored the role and practices surrounding CAM of all mainstream healthcare professionals 




Objective Three of this research determined what was lacking in the literature on the prevalence 
of CAM use amongst atopic eczema patients in a South African setting. This is the only African 
and South African study which demonstrates the extent of use of CAM for atopic eczema, the 
types of CAMs utilized, and the influence of demographic factors such as age, gender, race, 
ethnicity, socio-economic status and level of education on CAM use in atopic eczema. This study 
identified extensive (66%) CAM usage among atopic eczema patients in Durban, Kwa-Zulu 
Natal. This usage, which is amongst a larger sample population in comparison to other studies, 
was significantly higher than studies conducted in Europe, United Kingdom and the US. Race 
and religion and duration of the disease were significant predictors of CAM. It was found that 
cultural influences play a significant role in driving people to use CAM, with Indians and Muslims 
being the most frequent users. Additonally, this study identified the frequently used CAMs for 
atopic eczema to be vitamins, aromatherapy oils, herbal creams, traditional African medicines 
and homeopathy. The study further highlighted that CAM is mostly used in combination with 
conventional therapy and there was a reported poor patient disclosure to the dermatologist with 
regards to their CAM use. This paper is currently under review for publication in the accredited 
journal, Health SA Gesondheid. 
 
Chapter Five of this thesis, in press in South African Family Practice, presented the findings 
stemming from Objective Four on the knowledge, attitude and practices of healthcare 
professionals towards CAM for atopic eczema. This research discerned differences among 
mainstream healthcare professionals’ views and attitudes towards the use of CAM with the 
specialist group being the most sceptical surrounding its use. The findings established that there 
was poor communication between the healthcare professional and the patient surrounding CAM. 
The majority healthcare professionals did not initiate discussions nor discuss CAM with patients 
on request. The healthcare professionals in this study had very little knowledge of CAM, however, 
all acknowledged their lack of knowledge and indicated that they would like to be further educated 
with regards to the most recent evidence or lack of evidence of the common CAMs used for atopic 
eczema. It was found that CAM and conventional medicines are often used together. Considering 
this, the poor CAM knowledge and lack of communication between healthcare practitioners and 
patients found in this study have emphasized an urgent need for continuing education programmes 
on CAM and inclusion into undergraduate curriculums. It also highlights the need for healthcare 
professionals to communicate better with their patients regarding CAM use in light of the recent 




In conclusion, this work has accomplished its main aim through meeting its individual objectives. 
The findings from this thesis can be considered a key cornerstone in understanding CAM for 
atopic eczema and has contributed significantly to what was lacking in the literature globally, in 
Africa as well as South Africa. The work presented in this thesis has generated information 
essential in helping both patients and healthcare practitioners work together in order to help 
improve the outcome of atopic eczema.  
 
Figure 1 which follows, synthesizes diagrammatically, the study’s main objectives and how they 
were accomplished. It shows the key results stemming from this research and also highlights areas 









As each objective had its own limitations, these have been discussed in detail within the context 




The prevalence of CAM is high, has been on the rise and will continue to increase as the 
population becomes more health conscious and more well-read. CAM can therefore not be 
considered a ‘fad’ and its impact on healthcare has to be continuously researched. The following 
recommendations arise from this thesis:  
 
• This study identified frequently used CAMs; some of which many patients have reported 
positive results. An analysis of the efficacy of these specific CAMs in clinical trials, 
randomised, controlled and blinded, may be able to provide answers for possible 
integration of effective therapies into mainstream care. 
• The results from this study are a reflection of practices of patients in Durban, Kwa-Zulu 
Natal. It would be necessary for similar studies to be conducted in other regions of Kwa-
Zulu Natal and in other provinces in order to determine regional differences and ascertain 
if there is a similar trend amongst all patients in South Africa.  
• As above, studies amongst healthcare professionals in other regions would also be 
beneficial in ascertaining regional differences in their knowledge, attitude and practices. 
• The population of healthcare professionals in this research have indicated a dire need for 
more knowledge on CAM. Continuing education programmes on CAM for all healthcare 
professionals treating patients for atopic eczema should be offered regularly in seminars, 
talks, conferences or online.  
• Furthermore, establishing the extent of exposure to CAM taught within the current 
curriculum in all universities that train undergraduate doctors and pharmacists in South 
Africa would need to be conducted. Inclusion of appropriate CAM education in 
undergraduate programmes for all students is essential in preparing the next generation 
of professionals treating patients. These courses need to be structured and established 
within university curricula to meet the needs and trends of the local population.  
• Due to the large number of patients self-prescribing CAM and visiting alternative 
practitioners while on treatment with conventionally prescribed therapy; further studies 
investigating the costs of these CAMs and the costs of visits to CAM practitioners would 
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be uselful in helping ascertain the impact of this on the economy and the overall 
management of an atopic eczema patient. 
• A comparitive cost analysis study of CAM vs. conventional treatment would also help 
ascertain the financial impact of these medicines on the economy and in patients with 
atopic eczema. 
• From interviewing patients in both the public and private sector, it is apparent that there 
is a need for an establishment of an atopic eczema support center in local hospitals and 
clinics. This would allow more time for patients to get detailed advise on their medical 
treatment and interact in a more formal setting with others suffering from the same 
disease. A support center would help to better educate parents and caregivers on 
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